Supplementary Figures from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer

Authors:

YHYan Huang
Yan Huang
WHWei Hu
Wei Hu
JHJie Huang
Jie Huang
FSFangrong Shen
Fangrong Shen
YSYunjie Sun
Yunjie Sun
CICristina Ivan
Cristina Ivan
SPSunila Pradeep
Sunila Pradeep
RDRobert Dood
Robert Dood
MHMonika Haemmerle
Monika Haemmerle
DJDahai Jiang
Dahai Jiang
LMLingegowda S. Mangala
Lingegowda S. Mangala
KNKyunghee Noh
Kyunghee Noh

Open Access

Publisher website

Google Scholar

3 April 2023

other
Published by American Association for Cancer Research (AACR)

DOI:10.1158/1535-7163.22504614

Abstract

Supplementary Figure 1. In vitro effects of PR silencing on onapristone sensitivity in PR-high-expressing uterine cancer cell line (Ishikawa). Supplementary Figure 2. In vitro effects of onapristone and trametinib in PR-weak-expressing uterine cancer cell line (SKUT2). Supplementary Figure 3. In vivo effects of therapy with onapristone in uterine cancer model. Supplementary Figure 4. In vivo effect of onapristone, trametinib, and the combination of both drugs on total PR expression in the ISHIKAWA model.

Supplementary Figures from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer

Abstract

Keywords